CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.
As a result, the technology stands at a complicated intersection in the fight against a shifting climate. Breeding plants to ...
CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...
Two scientists won the 2020 Nobel Prize in Chemistry on Wednesday for creating genetic 'scissors' that can rewrite the code of life, contributing to new cancer therapies and holding out the prospect ...
The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...
In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...
Some conservation groups are calling for an effective ban on genetic modification, but others say these technologies are ...
Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback